{"lc": {"ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {"story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "user_code": "GOLD_16", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-22 18:31:35", "close_timestamp": 1637605895005, "created": "22/11/2021 18:31:35", "department": "English and Creative Writing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-22", "gender": "female", "id": "d9cde3e6-eeec-4a21-8053-de03211f0a27", "open_date_time": "2021-10-22 18:19:17", "open_timestamp": 1637605157675, "story_date": "2020-04-21 00:00:00", "story_source": "tpl", "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "summary": "A collaborative study by the University of Melbourne and Royal Melbourne Hospital has shown that Ivermectin, a US Food and Drug Administration-approved anti-parasitic drug, kills the SARS-CoV-2 virus.", "task_condition": "text", "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 737330, "what": "Ivermectin stopped the SARS-CoV-2 virus", "when_happened": "few_years_ago", "where_location": "Australia", "who": "Dr Kylie Wagstaff", "why": "Cure for SARS-CoV-2"}, "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "GOLD_16", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-22 18:48:17", "close_timestamp": 1637606897889, "created": "22/11/2021 18:48:19", "department": "English and Creative Writing", "disability": false, "ease": 2, "environment": "production", "experiment_date_datepicker": "2021-11-22", "gender": "female", "id": "ffb74fa3-c4b2-4c08-8968-9f511d08e62d", "open_date_time": "2021-10-22 18:40:18", "open_timestamp": 1637606418247, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA", "summary": "Issues and challenges in the production of the Novavax vaccine to fight against coronavirus and its various strains.", "task_condition": "viz", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 479642, "what": "Challenges in the production of Novavax vaccine", "when_happened": "few_month_ago", "where_location": "Mexico", "who": "Novavax/Vaccines", "why": "To create a vaccine, Novavax, against coronavirus"}, "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {"story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "user_code": "GOLD_16", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-22 18:39:54", "close_timestamp": 1637606394759, "created": "22/11/2021 18:39:56", "department": "English and Creative Writing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-11-22", "gender": "female", "id": "bd6c0293-0c8f-42d7-a27b-d5d7bdcbb87d", "open_date_time": "2021-10-22 18:31:49", "open_timestamp": 1637605909631, "story_date": "2020-08-20 00:00:00", "story_source": "tpl", "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "summary": "Thomas Borody, a Sydney-based gastroenterologist, urges Australian GPs to prescribe ivermectin triple therapy to end the coronavirus pandemic. The triple therapy is a combination of ivermectin, zinc, and doxycycline.\r\n\r\n", "task_condition": "text", "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 485128, "what": "Urging Australian GPs to prescribe ivermectin triple therapy to fight COVID-19", "when_happened": "few_month_ago", "where_location": "Australia", "who": "Thomas Borody", "why": "Cure for SARS-CoV-2"}, "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {"story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "user_code": "GOLD_16", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-22 18:56:52", "close_timestamp": 1637607412675, "created": "22/11/2021 18:56:54", "department": "English and Creative Writing", "disability": false, "ease": 2, "environment": "production", "experiment_date_datepicker": "2021-11-22", "gender": "female", "id": "5c2007e7-7c5f-499c-a6cd-5426c3c38696", "open_date_time": "2021-10-22 18:48:30", "open_timestamp": 1637606910822, "story_date": "2020-07-21 00:00:00", "story_source": "tpl", "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve", "summary": "Japan becomes the first country to approve Ronapreve as a medicine to fight against the COVID-19 virus.", "task_condition": "viz", "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 501853, "what": "Approving Ronapreve to fight the COVID-19 virus.", "when_happened": "few_month_ago", "where_location": "Japan", "who": "Dr Osamu Okuda", "why": "Cure for SARS-CoV-2"}}, "tb": {"pfizer": {"story_term": "pfizer", "user_code": "GOLD_16", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-22 19:19:22", "close_timestamp": 1637608762530, "created": "22/11/2021 19:19:24", "department": "English and Creative Writing", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-11-22", "gender": "female", "id": "5a0f3b2f-c312-4a6a-bb3f-1d7ba3802a61", "open_date_time": "2021-10-22 18:57:5", "open_timestamp": 1637607425952, "summary": "Pfizer: An Effective Vaccine to Fight Strains of SARS-CoV-2\r\nPfizer, a leading developer of coronavirus vaccines, has made tremendous progress by achieving a force-shield against the myriad strains of the COVID-19 virus. \r\nIn March of this year, the mRNA-based vaccine had proven to be effective in resisting the highly contagious P1 variant that spread throughout Brazil, despite the variants resistance and transmissibility. A recent study by the Public Health England (PHE) showed that Pfizer provided 88% protection against the B.1.617.2 variant, or the Indian variant, two weeks after a second dose, while protection afforded by two doses of Vaxzevria, from AstraZeneca, was about 60% against this strain after two weeks.\r\nIn its aim to prevent infection of the virus, the vaccine has not only fulfilled its primary function but also resisted mutated forms of the same.\r\n\r\n\r\n", "task_condition": "text", "task_key": "pfizer", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 1336578}, "astrazeneca": {"story_term": "astrazeneca", "user_code": "GOLD_16", "age_group": "21_30", "agreed": true, "close_date_time": "2021-10-22 19:35:58", "close_timestamp": 1637609758395, "created": "22/11/2021 19:35:59", "department": "English and Creative Writing", "disability": false, "ease": 1, "environment": "production", "experiment_date_datepicker": "2021-11-22", "gender": "female", "id": "5f0fe119-80b5-47e0-9f09-48f2a2f64b95", "open_date_time": "2021-10-22 19:19:35", "open_timestamp": 1637608775117, "summary": "AstraZeneca: A Fight Against the Virus and Governments\r\nSince its global rollout of the COVID-19 vaccine for the low and middle-income countries across the world through the multilateral COVAX initiative, AstraZeneca has been in the news for more than just a fight against the SARS-CoV-2. \r\nDue to the large gap between the supply and demand, Serum Institute of India (SII) - the sole producer of the vaccine, has been made to temporarily withhold it for the citizens of India by the Indian Government.\r\n\r\n ", "task_condition": "viz", "task_key": "astrazeneca", "task_level": "post_graduate_ma_msc", "time_taken_in_seconds": 983278}}}